Call Us: 1.800.873.5297


Pradaxa® Lawsuit News: Federal Court Imposes Sanctions Against Manufacturer of Pradaxa®, notes Schlichter, Bogard & Denton, LLP

Kristine Kraft, of the Pharmaceuticals and Medical Device Litigation Department at Schlichter, Bogard & Denton, LLP representing victims of dangerous pharmaceutical medications and unsafe medical devices, comments on Judge Herndon’s order imposing sanctions on the makers of Pradaxa® for their discovery violations. 


On December 9, 2013, the federal court presiding over the Pradaxa® multi-district litigation currently underway in the U.S. District Court, Southern District of Illinois, entered an order sanctioning Boehringer Ingelheim, the manufacturer of Pradaxa®, for continued discovery violations.  As stated in his 51-page order, Judge David Herndon was “stunned” by Boehringer’s “egregious” discovery violations.  The Court further found that Boehringer’s actions were in “bad faith,” and that monetary sanctions were warranted in the amount of $931,500.  (In re Pradaxa (Dabigatran Extexilate) Products Liability Litigation – MDL No. 2385)


Kristine Kraft, of Schlichter, Bogard & Denton, LLP, explains that this is the second time sanctions have been entered against the makers of Pradaxa® during this litigation.  In its September 18, 2013 decision, the Court ordered Boehringer to pay $29,540 in sanctions.  The order further stated that the Court was a firm believer in progressive discipline, and that Boehringer was required to abide by the discovery rules.


Plaintiffs filed a second motion for sanctions, alleging that Boehringer’s discovery abuses continued.  In the motion, plaintiffs alleged that Boehringer engaged in continuous violations of the discovery process by failing to produce or even identify discoverable information, allowing vital evidence to be destroyed, violating court orders, and making misrepresentations in open court.  As set forth in the December 9th order, Judge Herndon agreed, finding that “the reasonable inferences to be drawn from the actions of the defendant at this point in time are that such maneuverers are by design.”


The Court’s December 9th order indicates that the files of Professor Thorsten Lehr may be among the evidence that allegedly was destroyed by Boehringer.  Court documents describe Professor Lehr as a prominent scientist who played a key role in developing Pradaxa® and who authored a study that initially concluded that Pradaxa®’s safety was related to the therapeutic range of the drug.  The Court’s order explains that Professor Lehr’s desire to publicly disclose the existence of a therapeutic range for Pradaxa® was highly controversial within the company.  The order quotes Boehringer employee, Dr. Andreas Clemens, who stated: “The world is crying for this information – but the tricky part is that we have to tailor the messages smart.”  The order further states that, ultimately, Boehringer required that the study be revised to exclude information about therapeutic range.


According to Kraft: “The imposition of nearly one million dollars in sanctions against Boehringer sends a strong message that discovery violations are not to be taken lightly.  We will continue to zealously pursue this case until the individuals injured by Pradaxa® obtain the justice they deserve.”


About Schlichter, Bogard & Denton, LLP

Schlichter, Bogard & Denton, LLP is a unique law firm that aggressively represents its clients injured as a result of dangerous pharmaceutical medications and unsafe medical devices.  The attorneys Schlichter, Bogard & Denton, LLP who represent victims harmed by pharmaceutical manufacturers include Roger Denton, Kristine Kraft, Beth Wilkins Flieger, Ashley Brittain Landers, and Tara Rocque.  With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious injuries.  If you or a loved one has suffered from complications arising from the use of a pharmaceutical product, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.


The choice of a lawyer is an important decision and should not be based solely on advertisements.  Past results afford no guarantee of future results and every case is different and must be judged on its own merits.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.